Mirzai, Saeid http://orcid.org/0000-0002-2579-4965
Carbone, Salvatore
Batsis, John A.
Kritchevsky, Stephen B.
Kitzman, Dalane W.
Shapiro, Michael D.
Funding for this research was provided by:
Wake Forest University
Article History
Accepted: 3 May 2024
First Online: 16 May 2024
Compliance with Ethical Standards
:
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: Supported, in part, by the Wake Forest University Claude D. Pepper Older Americans Independence Center (P30 AG21332). Saeid Mirzai is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) (T32HL076132). John Batsis is supported, in part, by the National Institute on Aging of the NIH (R01-AG-077163). Dalane Kitzman is supported, in part, by the Kermit Glenn Phillips II Chair in Cardiovascular Medicine; NIH grants U01AG076928, R01AG078153, R01AG045551, R01AG18915, and U01HL160272; and grant funding from Novartis, Bayer, Novo Nordisk, Rivus, Pfizer, and AstraZeneca.
: Dalane Kitzman reports receiving honoraria as a consultant for Bayer, Corvia Medical, Boehringer Ingelheim, Ketyo, Rivus, Novo Nordisk, AstraZeneca, Pfizer, and Novartis and stock ownership in Gilead Sciences. Michael Shapiro has participated in scientific advisory boards with Amgen, Ionis, Novartis, and Precision BioScience and has served as a consultant for Ionis, Novartis, Regeneron, EmendoBio, and Aidoc.